FORUM FOSTERS DIALOGUE BETWEEN BREAST CANCER LIVED EXPERIENCE ADVOCATES, RESEARCHERS AND CLINICIANS Organised by the University of Queensland and Translational Research Institute
In October 2024, the Frazier Institute hosted an event dedicated to breast cancer advocacy and research, supported by TRI (Translational Research Institute), National Breast Cancer Foundation, PA Research Foundation, Health Translation Queensland, QUT and The University of Queensland Faculty of Medicine/Frazer Institute.
The key aim of the event co-organised by Associate Professor Joy Wolfram, Group Leader, Australian Institute for Bioengineering and Nanotechnology & School of Chemical Engineering, The University of Queensland was to foster dialogue between breast cancer lived experience advocates (consumers), researchers, and clinicians.
Co-organiser Associate Professor Fernando Guimaraes, Group Leader, Principal Research Fellow, Frazer Institute, The University of Queensland spoke to Australian Health Journal about the need to host the event and regularly engage with consumers.
Jo Maxwell, Principal Project Officer, Consumer and Community Involvement in Research Strategy and Support at The University of Queensland also spoke about the standards for consumer participation and collaboration adopted from the International Association for Public Participation (IAP2).
“IAP2 guides the researcher to structure consumer involvement all through the different stages of their research”, says Maxwell.
Associate Professor Cleola Anderiesz, Chief Executive Officer National Breast Cancer Foundation presented at the Forum and spoke to Australian Health Journal on the impact of engagement when communities, researchers and clinicians come together to hear about the latest research and discuss a future of better breast cancer care and outcomes.
The day long event was enlightening and impactful. The forum in Brisbane included a workshop focused on creating international connections between breast cancer consumers in Australia and the United States, with insights from leading breast cancer oncologists, clinicians, consumers, researchers, and community.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy.
Australian Health Journal met with 3 speakers at the recent ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Study on digital tool for pharmacists in aged care
In March 2022, the Australia government announced $350 million of funding over 4 years to employ on-site pharmacists in residential aged care, starting July 2023. In April 2023, the government made changes to the proposed on-site pharmacists, where the new program will now be delivered by and through community pharmacies. Regardless of how the model will be implemented, the goal remains the same – to improve quality use of medicines and medicines safety for aged care residents.
-
Updated handbook on chronic kidney disease management in primary care
Kidney Health Australia’s latest kidney disease guide for primary care practitioners is expected to be pivotal in slowing down the rates of kidney failure, which have doubled in the past 20 years and if left unchecked will grow by a further 42% by 2030, according to the health charity.
With specific reference to new kidney treatments and culturally safe kidney care for First Nations Australians, the 5th edition of Chronic Kidney Disease (CKD) Management in Primary Care handbook, known as the ‘kidney bible’, is a significant step-up in enabling earlier diagnosis of kidney disease for GPs and other front-line healthcare professionals.
